Arthropod- and Host-Specific Borrelia burgdorferi bbk32 Expression and the Inhibition of Spirochete Transmission
- 15 May 2000
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 164 (10), 5344-5351
- https://doi.org/10.4049/jimmunol.164.10.5344
Abstract
Antisera to BBK32 (a Borrelia burgdorferi fibronectin-binding protein) and BBK50, two Ags synthesized during infection, protect mice from experimental syringe-borne Lyme borreliosis. Therefore, B. burgdorferi bbk32 and bbk50 expression within Ixodes scapularis ticks and the murine host, and the effect of BBK32 and BBK50 antisera on spirochetes throughout the vector-host life cycle were investigated. bbk32 and bbk50 mRNA and protein were first detected within engorged ticks, demonstrating regulated expression within the vector. Then bbk32 expression increased in mice at the cutaneous site of inoculation. During disseminated murine infection, bbk32 and bbk50 were expressed in several murine tissues, and mRNA levels were greatest in the heart and spleen at 30 days. BBK32 antisera protected mice from tick-borne B. burgdorferi infection and spirochete numbers were reduced by 90% within nymphs that engorged on immunized mice. Moreover, 75% of these ticks did not retain spirochetes upon molting, and subsequent B. burgdorferi transmission by adult ticks was impaired. Larval acquisition of B. burgdorferi by I. scapularis was also inhibited by BBK32 antisera. These data demonstrate that bbk32 and bbk50 are expressed during tick engorgement and that BBK32 antisera can interfere with spirochete transmission at various stages of the vector-host life cycle. These studies provide insight into mechanisms of immunity to Lyme borreliosis and other vector-borne diseases.Keywords
This publication has 40 references indexed in Scilit:
- Fibronectin-binding activity in Borrelia burgdorferiBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1998
- Vaccination against Lyme Disease with RecombinantBorrelia burgdorferiOuter-Surface Lipoprotein A with AdjuvantNew England Journal of Medicine, 1998
- A Vaccine Consisting of RecombinantBorrelia burgdorferiOuter-Surface Protein A to Prevent Lyme DiseaseNew England Journal of Medicine, 1998
- Temporal pattern of Borrelia burgdorferi p21 expression in ticks and the mammalian host.Journal of Clinical Investigation, 1997
- Arthropod- and host-specific gene expression by Borrelia burgdorferi.Journal of Clinical Investigation, 1997
- Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.The Journal of Experimental Medicine, 1996
- Expression and sequence of outer surface protein C among North American isolates ofBorrelia burgdorferiFEMS Microbiology Letters, 1994
- Constructing polycompetitor cDNAs for quantitative PCRJournal of Immunological Methods, 1993
- Active immunization with pC protein ofBorrelia burgdorferi protects gerbils againstB. burgdorferi infectionInfection, 1992
- Protection of Mice Against the Lyme Disease Agent by Immunizing with Recombinant OspAScience, 1990